Editas Medicine
E661988
Editas Medicine is a biotechnology company focused on developing CRISPR-based gene-editing therapies to treat serious genetic diseases.
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
public company ⓘ |
| aimsToTreat |
hematologic diseases
ⓘ
inherited retinal diseases ⓘ serious genetic diseases ⓘ |
| collaboratedWith |
Allergan
NERFINISHED
ⓘ
Bristol Myers Squibb NERFINISHED ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
gene-editing therapies
ⓘ
genome editing medicines ⓘ |
| focusesOn |
CRISPR-based gene-editing therapies
ⓘ
ex vivo gene editing ⓘ genetic medicines ⓘ in vivo gene editing ⓘ |
| foundedBy |
David Liu
NERFINISHED
ⓘ
David R. Liu NERFINISHED ⓘ Feng Zhang NERFINISHED ⓘ Feng Zhang (scientist) NERFINISHED ⓘ George Church NERFINISHED ⓘ George M. Church NERFINISHED ⓘ J. Keith Joung NERFINISHED ⓘ Jennifer A. Doudna NERFINISHED ⓘ Jennifer Doudna NERFINISHED ⓘ Keith Joung NERFINISHED ⓘ Rodolphe Barrangou NERFINISHED ⓘ |
| foundingYear | 2013 ⓘ |
| hasClinicalTrials |
CRISPR-based therapies for blood disorders
ⓘ
CRISPR-based therapies for inherited retinal diseases ⓘ |
| hasIntellectualProperty | CRISPR gene-editing patents ⓘ |
| hasPipeline |
beta-thalassemia programs
ⓘ
inherited retinal disease programs ⓘ sickle cell disease programs ⓘ |
| hasWebsite | https://www.editasmedicine.com ⓘ |
| headquartersLocation | Cambridge, Massachusetts, United States NERFINISHED ⓘ |
| industry | biotechnology ⓘ |
| languageOfWorkOrName | English ⓘ |
| legalForm | corporation ⓘ |
| locatedInTimeZone | Eastern Time Zone ⓘ |
| researchArea |
genetic engineering
ⓘ
genome editing ⓘ hematologic malignancies ⓘ ocular diseases ⓘ |
| stockExchange | NASDAQ ⓘ |
| tickerSymbol | EDIT NERFINISHED ⓘ |
| usesTechnology |
CRISPR-Cas12a
NERFINISHED
ⓘ
CRISPR-Cas9 NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.